Selecting winning stocks in early 2026 requires looking beyond short-term noise, as U.S. equities respond to easing inflation ...

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...

The biotech is advancing a bispecific medicine aimed at two popular targets and being billed as a potential therapeutic ...

The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...

AbbVie stock (NYSE:ABBV) has exhibited considerable rally potential, having once achieved over a 50% increase in less than two months in 2020. Furthermore, the stock has undergone seven rallies ...

AbbVie's major drugs, Skyrizi and Rinvoq, are generating lots of sales. Realty Income's diversified portfolio provides plenty of protection and monthly income. The JEPQ ETF employs a covered-call ...

Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease affecting the large intestine, causing persistent inflammation and ulceration of the colon’s lining. Common symptoms include ...

SKYRIZI ® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s ...

To better understand which social media platforms Americans use, Pew Research Center surveyed 5,022 U.S. adults from Feb. 5 to June 18, 2025. SSRS conducted this National Public Opinion Reference ...

A growing number of special education teachers say they use artificial intelligence platforms to draft all or part of students’ individualized education programs, even as many districts lack policies ...